127 related articles for article (PubMed ID: 34454786)
1. Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants.
Kurokawa N; Robinson MK; Bernard C; Kawaguchi Y; Koujin Y; Koen A; Madhi S; Polasek TM; McNeal M; Dargis M; Couture MM; Trépanier S; Forrest BD; Tsutsui N
Vaccine; 2021 Sep; 39(39):5513-5523. PubMed ID: 34454786
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
Lancet Infect Dis; 2017 Aug; 17(8):843-853. PubMed ID: 28483414
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.
Coates EE; Edupuganti S; Chen GL; Happe M; Strom L; Widge A; Florez MB; Cox JH; Gordon I; Plummer S; Ola A; Yamshchikov G; Andrews C; Curate-Ingram S; Morgan P; Nagar S; Collins MH; Bray A; Nguyen T; Stein J; Case CL; Kaltovich F; Wycuff D; Liang CJ; Carlton K; Vazquez S; Mascola JR; Ledgerwood JE;
Lancet Infect Dis; 2022 Aug; 22(8):1210-1220. PubMed ID: 35568049
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of a plant-derived rotavirus-like particle vaccine.
Kurokawa N; Lavoie PO; D'Aoust MA; Couture MM; Dargis M; Trépanier S; Hoshino S; Koike T; Arai M; Tsutsui N
Vaccine; 2021 Aug; 39(35):4979-4987. PubMed ID: 34325930
[TBL] [Abstract][Full Text] [Related]
6. A randomized Phase I/II study to evaluate safety and reactogenicity of a heat-stable rotavirus vaccine in healthy adults followed by evaluation of the safety, reactogenicity, and immunogenicity in infants.
Kanchan V; Zaman K; Aziz AB; Zaman SF; Zaman F; Haque W; Khanam M; Karim MM; Kale S; Ali SK; Goveia MG; Kaplan SS; Gill D; Khan WA; Yunus M; Singh A; Clemens JD
Hum Vaccin Immunother; 2020 Mar; 16(3):693-702. PubMed ID: 31526218
[No Abstract] [Full Text] [Related]
7. Safety and immunogenicity of a novel oral hexavalent rotavirus vaccine：a phase I clinical trial.
Wu ZW; Li QL; Zhou HS; Duan K; Gao Z; Zhang XJ; Jiang ZJ; Hao ZY; Jin F; Bai X; Li Q; Xu GL; Zhao YL; Yang XM
Hum Vaccin Immunother; 2021 Jul; 17(7):2311-2318. PubMed ID: 33545015
[No Abstract] [Full Text] [Related]
8. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico.
López-Macías C; Ferat-Osorio E; Tenorio-Calvo A; Isibasi A; Talavera J; Arteaga-Ruiz O; Arriaga-Pizano L; Hickman SP; Allende M; Lenhard K; Pincus S; Connolly K; Raghunandan R; Smith G; Glenn G
Vaccine; 2011 Oct; 29(44):7826-34. PubMed ID: 21816199
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a Third Scheduled Dose of Rotarix in Australian Indigenous Infants: A Phase IV, Double-blind, Randomized, Placebo-Controlled Clinical Trial.
Middleton BF; Danchin M; Jones MA; Leach AJ; Cunliffe N; Kirkwood CD; Carapetis J; Gallagher S; Kirkham LA; Granland C; McNeal M; Marsh JA; Waddington CS; Snelling TL
J Infect Dis; 2022 Nov; 226(9):1537-1544. PubMed ID: 35134951
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.
Zeng G; Wu Q; Pan H; Li M; Yang J; Wang L; Wu Z; Jiang D; Deng X; Chu K; Zheng W; Wang L; Lu W; Han B; Zhao Y; Zhu F; Yu H; Yin W
Lancet Infect Dis; 2022 Apr; 22(4):483-495. PubMed ID: 34890537
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial.
Bennett SR; McCarty JM; Ramanathan R; Mendy J; Richardson JS; Smith J; Alexander J; Ledgerwood JE; de Lame PA; Royalty Tredo S; Warfield KL; Bedell L
Lancet Infect Dis; 2022 Sep; 22(9):1343-1355. PubMed ID: 35709798
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults.
Fix AD; Harro C; McNeal M; Dally L; Flores J; Robertson G; Boslego JW; Cryz S
Vaccine; 2015 Jul; 33(31):3766-72. PubMed ID: 26065919
[TBL] [Abstract][Full Text] [Related]
16. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults.
Treanor JJ; Atmar RL; Frey SE; Gormley R; Chen WH; Ferreira J; Goodwin R; Borkowski A; Clemens R; Mendelman PM
J Infect Dis; 2014 Dec; 210(11):1763-71. PubMed ID: 24951828
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine.
Danchin M; Kirkwood CD; Lee KJ; Bishop RF; Watts E; Justice FA; Clifford V; Cowley D; Buttery JP; Bines JE
Vaccine; 2013 May; 31(23):2610-6. PubMed ID: 23597719
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
[TBL] [Abstract][Full Text] [Related]
20. Neonatal rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant administration schedule in Malawi: a randomised, double-blind, four-arm parallel group dose-ranging study.
Witte D; Handley A; Jere KC; Bogandovic-Sakran N; Mpakiza A; Turner A; Pavlic D; Boniface K; Mandolo J; Ong DS; Bonnici R; Justice F; Bar-Zeev N; Iturriza-Gomara M; Ackland J; Donato CM; Cowley D; Barnes G; Cunliffe NA; Bines JE
Lancet Infect Dis; 2022 May; 22(5):668-678. PubMed ID: 35065683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
